Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The main objectives of this study are to determine the safety profile of briciclib, an
experimental anti-cancer drug, as it is administered intravenously once weekly as escalating
doses in adult patients with advanced cancer and solid tumors, and to determine the highest
dose of briciclib that can be safely given. Secondary objectives are to determine how the
amount of briciclib in circulation changes over time and how much briciclib gets into the
urine for excretion, and to document potential anti-tumor effects of briciclib.